Combined CDK4/6 and ERK1/2 inhibition enhances anti-tumor activity in NF1-associated plexiform neurofibroma.
Alyssa C FlintDana K MitchellSteven P AngusAbbi Elise SmithWaylan BesslerLi JiangHenry Elmer MangXiaohong LiQingbo LuBrooke E HickeyGeorge E SanduskyAndrea R MastersChi ZhangPengtao DangJenna K KoenigGary L JohnsonWeihua ShenJiangang LiuAmit AggarwalGregory P DonohoMelinda D WillardShripad V BhagwatD Wade ClappSteven D RhodesPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
These findings provide rationale for the clinical translation of CDK4/6 inhibitors alone and in combination with therapies targeting the RAS/MAPK pathway for the treatment of PNF and other peripheral nerve sheath tumors in persons with NF1.